N-PHENYLARYLSULFONAMIDVERBINDUNG, ARZNEIMITTEL DAS DIESE VERBINDUNG ALS WIRKSTOFF ENTHÄLT, ZWISCHENPRODUKT FÜR DIE VERBINDUNG UND VERFAHREN ZU DESSEN HERSTELLUNG
An N-phenylarylsulfonylamide compound of formula (I) (R 1 is COOH etc .; R 2 is hydrogen, methyl, etc .; R 3 and R 4 are a combination of methyl and methyl, etc .; R 5 is isopropyl etc .; Ar is thiazolyl, pyridyl, 5-methyl-2-furyl each optionally substituted with methyl; n is zero or 1), a synthetic...
Gespeichert in:
Hauptverfasser: | , , , , , |
---|---|
Format: | Patent |
Sprache: | ger |
Schlagworte: | |
Online-Zugang: | Volltext bestellen |
Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
Zusammenfassung: | An N-phenylarylsulfonylamide compound of formula (I)
(R 1 is COOH etc .; R 2 is hydrogen, methyl, etc .; R 3 and R 4 are a combination of methyl and methyl, etc .; R 5 is isopropyl etc .; Ar is thiazolyl, pyridyl, 5-methyl-2-furyl each optionally substituted with methyl; n is zero or 1), a synthetic intermediate for the compound and a process for its preparation. The compound of formula (I) binds to a prostaglandin E 2 receptor, especially an EP 1 subtype receptor, and antagonizes it. It is less affected by protein binding, so it has a satisfactory in vivo activity. Therefore, it is considered to be useful as an analgesic, an antipyretic agent, an agent for the treatment of pollakiuria (frequent urination) and/or lower urinary tract disease syndrome or an antineoplastic agent. |
---|